Published • loading... • Updated
Moderna stock soars 177%, Merck jumps 12% after cancer vaccine shows promise in late-stage trial
- On Wednesday, Merck and Moderna announced that a personalized mRNA-based cancer vaccine succeeded in a Phase 3 trial, significantly reducing recurrence risk in high-risk melanoma patients when paired with Merck's Keytruda immunotherapy.
- Previous Phase 2b trial results established the efficacy baseline, showing the treatment reduced melanoma recurrence by 49% and metastasis to distant organs by 59% in patients after surgical tumor removal.
- H. Lee Moffitt Cancer Center & Research Institute oncologist Dr. Ahmad Tarhini called the approach "individualized neoantigen therapy," explaining that genetic sequencing creates a "unique mutational fingerprint" to help the immune system attack cancer.
- Moderna president Stephen Hoge said the vaccine could be available by next year if regulators approve the treatment, though the FDA must first review full data the companies plan to present soon.
- Expanding beyond melanoma, where the American Cancer Society expects 112,000 new cases in 2026, mRNA technology is currently in trials for bladder, kidney, lung, stomach, and pancreatic cancers.
Insights by Ground AI
4 Articles
4 Articles
Moderna, in collaboration with Merck, achieved success in Phase 3 clinical trials for a personalized mRNA cancer vaccine. Significant results were obtained in high-risk melanoma patients, demonstrating a reduction in the risk of recurrence and metastasis, leading to a surge in the stock price amidst high market valuations. While the challenge of optimizing the production process remains, the initiative has demonstrated the potential for a succes…
Moderna shares double as cancer vaccine data rekindles investor hopes
Moderna shares more than doubled on Wednesday, adding about $30 billion to its market value, after promising late-stage data on its personalized mRNA cancer therapy developed with Merck sent investors piling into the stock.
·London, United Kingdom
Read Full ArticleCoverage Details
Total News Sources4
Leaning Left1Leaning Right1Center2Last UpdatedBias Distribution50% Center
Bias Distribution
- 50% of the sources are Center
50% Center
L 25%
C 50%
R 25%
Factuality
To view factuality data please Upgrade to Premium
